IQV 8-K Current Reports

Material AgreementsFinancial EventsExhibits & Filings

IQVIA Holdings 8-K Report, Financial Results (Oct 27, 2026)

IQVIA Holdings Inc. reported record third-quarter 2026 results, with revenue of $4,428 million, up 8.0% year-over-year (8.6% at constant currency). GAAP net income was $350 million and GAAP diluted EPS was $2.10. Adjusted EBITDA rose to $1,032 million, up 8.7%, and Adjusted Diluted EPS was $3.34, up 11.3%. R&D Solutions net new bookings reached $3.2 billion, up 15%, with a book-to-bill ratio of 1.2x. Management cited favorable demand indicators and said its organic growth acceleration was double the prior rate for Commercial Solutions and nearly triple for clinical. The company also adjusted R&DS contracted backlog following a review of inactive trials. The backlog adjustment was approximately $2.1 billion and, per the filing, had no impact on historical financial results, 2026 guidance, book-to-bill, or next-twelve-month revenue from backlog. R&DS contracted backlog stood at $32.6 billion as of September 30, 2026, with approximately $9.4 billion expected to convert to revenue in the next twelve months, representing 10% year-over-year growth. IQVIA raised its full-year 2026 guidance for revenue to $17,350 million–$17,500 million, Adjusted EBITDA to $4,025 million–$4,055 million, and Adjusted Diluted EPS to $12.90–$13.00. Net debt was $13,818 million and the Net Leverage Ratio was 3.45x trailing twelve-month Adjusted EBITDA. Free cash flow for the quarter was $667 million, equal to 120% of Adjusted Net Income. The company will hold an Investor Day on December 1, 2026.

Oct 27, 2026 8-K

IQVIA Holdings 8-K Report, Material Agreement (Sep 23, 2026)

On September 23, 2026, IQVIA Inc., a wholly owned subsidiary of IQVIA Holdings Inc., completed the issuance and sale of $2.0 billion in gross proceeds of 6.375% senior notes due 2034. The notes were issued under an indenture dated the same day among the Issuer, U.S. Bank Trust Company, National Association, as trustee, and certain subsidiaries of the Issuer as guarantors. The notes are unsecured obligations of the Issuer and mature on March 15, 2034, unless earlier repurchased or redeemed. The filing states that the net proceeds will be used to redeem in full the Issuer's Senior 5.000% Notes due 2026, to repay a portion of the outstanding indebtedness under the Issuer's revolving credit facility, and to pay fees and expenses related to the offering. This refinancing replaces existing debt, including a revolver balance, with longer-dated fixed-rate notes. Interest is payable semi-annually on March 15 and September 15, beginning March 15, 2027. The Issuer may redeem the notes before maturity at a customary make-whole premium at any time before September 15, 2029, subject to a customary equity claw redemption right. After that date, the redemption premium declines from 3.188% to 0.000%. The indenture is filed as Exhibit 4.1, and the filing incorporates the description of the notes under Item 2.03 as well.

Sep 23, 2026 8-K

IQVIA Holdings 8-K Report, Corporate Update (Sep 9, 2026)

IQVIA Holdings Inc. (NYSE: IQV) disclosed on September 9, 2026 that its wholly owned subsidiary, IQVIA Inc. (the "Issuer"), intends to raise $2,000,000,000 in gross proceeds through an offering of senior notes due 2034 and priced the offering. The Issuer entered into a purchase agreement with the representative of the purchasers for $2.0 billion in aggregate principal amount of senior notes bearing interest at 6.375% per annum. The company states that the net proceeds will be used to redeem in full the Issuer's Senior 5.000% Notes due 2026, to repay a portion of the outstanding indebtedness under the Issuer's revolving credit facility, and to pay fees and expenses related to the offering. The notes will pay interest semi-annually on March 15 and September 15, beginning March 15, 2027, and will mature on March 15, 2034. Closing is expected on or about September 23, 2026, subject to customary closing conditions. The notes are being offered in reliance on Rule 144A and Regulation S and have not been registered under the Securities Act. The filing is a refinancing and debt-management transaction that replaces the 5.000% notes due 2026 and reduces revolving credit facility borrowings.

Sep 9, 2026 8-K

Material AgreementsFinancial EventsExhibits & Filings

IQVIA Holdings 8-K Report, Financial Results (Jul 28, 2026)

IQVIA Holdings Inc. furnished an 8-K under Item 2.02 on July 28, 2026, attaching a press release reporting results for the second quarter ended June 30, 2026. Revenue was $4,368 million, up 8.7% year-over-year on a reported basis, with GAAP net income of $256 million, GAAP diluted EPS of $1.53, Adjusted EBITDA of $994 million (up 9.2%), and Adjusted Diluted EPS of $3.15 (up 12.1%). R&D Solutions net new bookings were $3.15 billion, up 19% year-over-year, with a 1.22x book-to-bill ratio. Results are presented under the company's new two-segment structure, Commercial Solutions and Research & Development Solutions, effective January 1, 2026. Management raised full-year 2026 guidance for revenue to $17,275 million to $17,475 million, Adjusted EBITDA to $4,000 million to $4,050 million, and Adjusted Diluted EPS to $12.80 to $13.00. The filing attributes the revenue raise to approximately 100 basis points higher organic growth and about 50 basis points higher M&A contribution, partly offset by roughly 80 basis points of unfavorable foreign exchange versus prior guidance. Balance sheet metrics show cash of $1,909 million, debt of $15,999 million, net debt of $14,090 million, and a Net Leverage Ratio of 3.59x trailing twelve-month Adjusted EBITDA. Second-quarter operating cash flow was $558 million and free cash flow was $360 million. The company repurchased $398 million of stock in the quarter, with $2,819 million of authorization remaining as of June 30, 2026.

Jul 28, 2026 8-K

IQVIA Holdings 8-K Report, Material Agreement (Jun 11, 2026)

On June 11, 2026, IQVIA Inc., a wholly owned subsidiary of IQVIA Holdings Inc., completed the issuance and sale of €950,000,000 in gross proceeds of 4.625% senior notes due 2033. The Notes were issued under an Indenture dated June 11, 2026, among IQVIA Inc., U.S. Bank Trust Company, National Association, as trustee, and certain subsidiaries of the Issuer as guarantors. The Notes are unsecured obligations of the Issuer and bear interest payable semi-annually on June 15 and December 15, beginning December 15, 2026. The net proceeds will be used to refinance certain of the Issuer's existing indebtedness and to pay fees and expenses related to the offering. The filing also states the Issuer may redeem the Notes before their June 15, 2033 maturity, subject to a customary make-whole premium at any time before June 15, 2029 (with a customary equity claw redemption right), and thereafter at a redemption premium declining from 2.313% to 0.000%. The filing is limited to the debt issuance itself, reported under Item 1.01 (Material Definitive Agreement) and Item 2.03 (Direct Financial Obligation), with the Indenture filed as Exhibit 4.1.

Jun 11, 2026 8-K

IQVIA Holdings 8-K Report, Corporate Update (Jun 4, 2026)

IQVIA Holdings Inc. (NYSE: IQV) reported in this Form 8-K, filed June 4, 2026, that its wholly owned subsidiary, IQVIA Inc. (the "Issuer"), priced an offering of €950,000,000 in aggregate principal amount of senior notes due 2033. The notes bear interest at 4.625% per annum, payable semi-annually in arrears on June 15 and December 15, beginning December 15, 2026, and mature on June 15, 2033, unless earlier repurchased or redeemed. The Issuer entered into a purchase agreement with the representative of the purchasers named therein, and closing is expected on or about June 11, 2026, subject to customary closing conditions. According to the attached pricing press release (Exhibit 99.1), proceeds will be used to refinance certain of the Issuer's existing indebtedness and to pay fees and expenses related to the offering. The notes have not been registered under the Securities Act and are being offered only to qualified institutional buyers under Rule 144A and to non-U.S. investors under Regulation S, by means of a private offering memorandum. For investors, the filing is a debt financing and refinancing event rather than an operating or earnings update. The filing identifies the completion of the offering as contingent on customary closing conditions, and its forward-looking statements cite the failure to consummate the offering and changes in market conditions as risk factors.

Jun 4, 2026 8-K

IQVIA Holdings 8-K Report, Corporate Update (Jun 3, 2026)

IQVIA Holdings Inc. (NYSE: IQV) disclosed in a Form 8-K filed June 3, 2026 that its wholly owned subsidiary, IQVIA Inc. (the "Issuer"), intends to raise €950,000,000 in gross proceeds through an offering of senior notes due 2033. The offering is intended to refinance certain of the Issuer's existing indebtedness and to pay fees and expenses related to the offering. The filing is a notice of intent under Item 8.01 (Other Events) and attaches a launch press release as Exhibit 99.1. The press release states that completion of the offering is subject to market and other customary conditions, so the timing and final size of the issuance are not confirmed in this filing. The notes are being offered under Rule 144A to qualified institutional buyers in the United States and under Regulation S outside the United States, and have not been registered under the Securities Act of 1933. For investors, the key takeaway is a planned refinancing of existing debt at the Issuer level, denominated in euros, with a 2033 maturity. The filing does not disclose the coupon, pricing, or the specific debt being refinanced. The press release notes that the offering's failure to close is a forward-looking risk.

Jun 3, 2026 8-K

IQVIA Holdings 8-K Report, Corporate Update (May 7, 2026)

IQVIA Holdings Inc. (IQV) filed a Form 8-K on May 7, 2026 to disclose that its board of directors authorized the repurchase of an additional $2,000 million of the company's common stock under its existing equity repurchase program (the "Repurchase Program"). The filing states this brings the total remaining authorization to $3,217 million, which the accompanying press release rounds to $3.2 billion. The filing emphasizes that the Repurchase Program does not obligate the company to buy any particular amount of stock and may be modified, extended, suspended or discontinued at any time. Timing and amount of repurchases are set by management based on factors including the market price of the stock, corporate requirements and overall market conditions. Purchases may occur in open market transactions through a broker-dealer, in block trades, or in privately negotiated transactions, and the program has no expiration date. The company also states that it has, from time to time, repurchased shares through private or other transactions outside the Repurchase Program, and that it may discontinue repurchases without notice. The press release, filed as Exhibit 99.1, is titled "IQVIA Board of Directors Approves $2 Billion Increase in Share Repurchase Authorization" and describes IQVIA as a global provider of clinical research services, commercial insights and healthcare intelligence.

May 7, 2026 8-K

Leadership ChangesShareholder MattersExhibits & Filings

IQVIA Holdings 8-K Report, Financial Results (May 5, 2026)

IQVIA Holdings Inc. (NYSE: IQV) furnished its press release reporting first-quarter 2026 results for the quarter ended March 31, 2026, under Item 2.02 of Form 8-K. Revenue was $4,151 million, up 8.4% on a reported basis and 6.0% at constant currency. GAAP net income attributable to IQVIA was $274 million, or $1.61 per diluted share, and Adjusted EBITDA was $932 million, up 5.5% year-over-year. Adjusted diluted EPS was $2.90, up 7.4%. Commercial Solutions revenue grew 11.6% on a reported basis to $1,754 million, while R&D Solutions revenue rose 6.2% to $2,397 million. The company now reports two segments, Commercial Solutions and Research & Development Solutions, following a reorganization effective January 1, 2026. R&DS contracted backlog stood at $34.2 billion at quarter-end, with net new bookings of $2.5 billion and a book-to-bill ratio of 1.04x for the quarter. The company expects approximately $8.9 billion of backlog to convert to revenue in the next twelve months. Operating cash flow was $618 million and free cash flow was $491 million, up 15% year-over-year. IQVIA repurchased $552 million of common stock in the quarter and had $1,217 million of authorization remaining. Net debt was $13,886 million, and the Net Leverage Ratio was 3.62x trailing twelve-month Adjusted EBITDA. For full-year 2026, IQVIA reaffirmed revenue guidance of $17,150 million to $17,350 million and Adjusted EBITDA guidance of $3,975 million to $4,025 million, and raised Adjusted Diluted EPS guidance to $12.65 to $12.95. Revenue guidance assumes about 150 basis points of acquisition contribution and an approximately 100 basis point foreign exchange tailwind.

May 5, 2026 8-K

IQVIA Holdings 8-K Report, Executive Changes (Apr 23, 2026)

On April 23, 2026, IQVIA Holdings Inc. held its 2026 Annual Meeting of Stockholders, where stockholders approved the IQVIA Holdings Inc. 2026 Incentive and Stock Award Plan (the "2026 Plan"). The 2026 Plan took effect immediately upon approval and replaces the 2017 Incentive and Stock Award Plan (the "2017 Plan"), with any shares remaining under the 2017 Plan assumed by the 2026 Plan. It authorizes stock options (incentive and non-qualified), stock appreciation rights, restricted stock awards, restricted stock units, and stock awards. Performance-based awards vest based on metrics set by the Leadership Development and Compensation Committee, which may include revenue, adjusted EBITDA, earnings per share, adjusted diluted earnings per share, cash flow, free cash flow as a percentage of adjusted net income, and relative total stockholder return. The Committee also approved new forms of award agreements for stock appreciation rights, performance shares, restricted stock units, and cash-settled restricted stock units for use under the plan. At the meeting, stockholders elected nine directors to one-year terms, ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2026, and approved, on an advisory basis, the 2025 compensation of the named executive officers. Stockholders did not approve the advisory proposal concerning separate Chairman and Chief Executive Officer roles, which received 36,717,802 votes for and 111,154,252 votes against. The record date share count was 167,866,339 shares of common stock. The 2026 Plan's material terms are described in the company's definitive proxy statement filed February 27, 2026. The full plan and the forms of award agreements are filed as Exhibits 10.1 through 10.5 to this Form 8-K.

Apr 23, 2026 8-K

Material AgreementsFinancial EventsExhibits & Filings

IQVIA Holdings 8-K Report, Financial Results (Feb 5, 2026)

IQVIA Holdings Inc. (NYSE: IQV) furnished an 8-K on February 5, 2026 under Item 2.02 attaching a press release reporting preliminary, unaudited fourth-quarter and full-year 2025 results and full-year 2026 guidance. For Q4 2025, revenue was $4,364 million, up 10.3% reported and 8.1% at constant currency; GAAP net income was $514 million and GAAP diluted EPS was $2.99, while Adjusted Diluted EPS was $3.42 and Adjusted EBITDA was $1,046 million. For full-year 2025, revenue was $16,310 million, up 5.9% reported, GAAP net income was $1,360 million (down 0.9%), and Adjusted Diluted EPS was $11.92. Operating cash flow for 2025 was $2,654 million and free cash flow was $2,051 million, equal to 99% of Adjusted Net Income. R&D Solutions contracted backlog reached $32.7 billion, up 5.3% year-over-year, with a Q4 book-to-bill ratio of 1.18x. At year-end, cash was $1,980 million, debt was $15,724 million, net debt was $13,744 million, and the Net Leverage Ratio was 3.63x. The company repurchased $1,244 million of stock in 2025 and had $1,769 million of authorization remaining. For 2026, IQVIA guided to revenue of $17,150 million to $17,350 million, Adjusted EBITDA of $3,975 million to $4,025 million, and Adjusted Diluted EPS of $12.55 to $12.85. The guidance includes about 150 basis points of contribution from acquisitions, about 100 basis points of foreign exchange tailwind, and roughly $80 million of higher interest expense. Effective January 1, 2026, the company is reorganizing its segments: CSMS is folded into TAS, which is renamed Commercial Solutions, and Real-World Late Phase and certain other Real-World offerings move into R&DS. Segment recast figures for 2025 and 2024 are provided.

Feb 5, 2026 8-K

IQVIA Holdings 8-K Report, Material Agreement (Dec 9, 2025)

IQVIA Holdings Inc. filed a Form 8-K reporting that on December 9, 2025 it entered into Amendment No. 5 to its Fifth Amended and Restated Credit Agreement. The amendment refinances its Term A-1 Dollar Loans and Term A-2 Dollar Loans into a new class of term A dollar loans, refinances its Term A Euro Loans into a new class of term A euro loans, and refinances all current U.S., Japanese and Swiss/Multicurrency Revolving Credit Commitments into a new class of revolving credit commitments. The amendment also reduces the interest rate on U.S. dollar term A loans and U.S. dollar revolving credit loans by eliminating the term SOFR credit spread adjustment. In addition, it releases the Swiss Subsidiary Borrower and the Japanese Borrower from all obligations as borrowers under the Credit Agreement. The filing states that the Amendment is being reported under Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation). The filing does not state any dollar amounts, borrowing sizes or rate levels for the refinanced facilities. The full terms are in the Amendment, filed as Exhibit 10.1, with Bank of America, N.A. as administrative agent and collateral agent.

Dec 9, 2025 8-K

IQVIA Holdings 8-K Report, Executive Changes (Nov 5, 2025)

IQVIA Holdings Inc. filed this Current Report on Form 8-K dated November 5, 2025, to disclose the Board of Directors' appointment of William G. Kaelin Jr., M.D. to the Board on that date. The Board determined that Dr. Kaelin satisfies the New York Stock Exchange definition of "independent director." He will participate in the non-employee director compensation arrangements described in the company's proxy statement dated February 28, 2025, and is expected to enter into the company's standard indemnification agreement with non-management directors. The company also issued a press release announcing the appointment, furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure). That press release describes Dr. Kaelin as a Senior Physician-Scientist at Brigham and Women's Hospital, Sidney Farber Professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School, and an Investigator at the Howard Hughes Medical Institute. It notes that he shared the 2019 Nobel Prize in Physiology or Medicine and that he serves on the board of Eli Lilly and Company, where he chairs the Science and Technology Committee. Chairman and CEO Ari Bousbib is quoted welcoming him to the board. The filing contains no financial results, guidance, or transaction disclosures. Its investor relevance is limited to board refreshment and the addition of an independent director with scientific and oncology expertise.

Nov 5, 2025 8-K

IQVIA Holdings 8-K Report, Financial Results (Oct 28, 2025)

IQVIA Holdings Inc. filed this Form 8-K on October 28, 2025 to furnish its press release reporting results for the third quarter ended September 30, 2025. Third-quarter revenue was $4,100 million, up 5.2 percent on a reported basis and 3.9 percent at constant currency. GAAP net income attributable to IQVIA was $331 million, or $1.93 per diluted share, and Adjusted EBITDA was $949 million, up 1.1 percent year-over-year. Adjusted diluted EPS was $3.00. Free cash flow was $772 million, up 35 percent year-over-year, equal to 150 percent of Adjusted Net Income. By segment, Technology & Analytics Solutions (TAS) revenue was $1,631 million, up 5.0 percent reported, and Research & Development Solutions (R&DS) revenue was $2,260 million, up 4.5 percent reported. R&DS delivered $2.6 billion of quarterly bookings, a book-to-bill ratio of 1.15x, and contracted backlog of $32.4 billion, up 4.1 percent year-over-year. Contract Sales & Medical Solutions (CSMS) revenue was $209 million, up 16.1 percent reported. Management cited R&DS bookings growth of 13 percent year-over-year and RFP growth of 20 percent. Balance sheet leverage stood at a Net Leverage Ratio of 3.52x trailing twelve-month Adjusted EBITDA, with net debt of $13,143 million. For full-year 2025, IQVIA reaffirmed the midpoint of its guidance and narrowed ranges: revenue of $16,150 million to $16,250 million, Adjusted EBITDA of $3,775 million to $3,800 million, and Adjusted Diluted EPS of $11.85 to $11.95. The revenue guidance includes approximately $100 million of COVID-related revenue step-down, entirely in R&DS.

Oct 28, 2025 8-K

IQVIA Holdings 8-K Report, Executive Changes (Sep 2, 2025)

IQVIA Holdings Inc. (IQV) announced a planned leadership transition in its finance organization. Michael J. Fedock, currently Senior Vice President, Financial Planning and Analysis, will succeed Ronald E. Bruehlman as Executive Vice President and Chief Financial Officer effective February 28, 2026. The change is part of the Company's previously announced CFO succession plan. Fedock, age 50, joined the Company in 2016 and has more than 25 years of healthcare industry experience. He previously served as CFO of the Research & Development Solutions Business Unit (July 2019 to April 2021) and as CFO of IQVIA Laboratories (May 2016 to July 2019). In connection with his promotion, his annual base salary will increase to $750,000, with an annual cash incentive target of 100% of base salary and eligibility for annual Long Term Incentive cycles under the Company's 2017 Incentive and Stock Award Plan. Bruehlman will retire as CFO effective February 28, 2026, and transition to Senior Advisor to CEO Ari Bousbib. The filing describes the move as ensuring continuity and a seamless transition. The announcement was made through a press release dated September 2, 2025, furnished as Exhibit 99.1.

Sep 2, 2025 8-K

Material AgreementsFinancial EventsExhibits & Filings

IQVIA Holdings 8-K Report, Financial Results (Jul 22, 2025)

IQVIA Holdings Inc. filed this Form 8-K under Item 2.02 (Results of Operations and Financial Condition) to furnish its press release reporting second-quarter 2025 results for the quarter ended June 30, 2025. Revenue was $4,017 million, up 5.3 percent on a reported basis and 3.6 percent at constant currency. GAAP Net Income was $266 million and GAAP Diluted EPS was $1.54, while Adjusted EBITDA was $910 million and Adjusted Diluted EPS was $2.81. TAS revenue of $1,628 million grew 8.9 percent reported, R&DS revenue of $2,201 million grew 2.5 percent reported, and R&DS contracted backlog reached $32.1 billion, up 5.1 percent year-over-year. R&DS quarterly bookings were $2.5 billion, a book-to-bill ratio of 1.12x. The company updated full-year 2025 guidance to revenue of $16,100 million to $16,300 million, Adjusted EBITDA of $3,750 million to $3,825 million, and Adjusted Diluted EPS of $11.75 to $12.05. The guidance assumes approximately $100 million of COVID-related revenue step-down, entirely in R&DS. As of June 30, 2025, cash and cash equivalents were $2,039 million, debt was $15,490 million, and net debt was $13,451 million, a Net Leverage Ratio of 3.61x trailing twelve-month Adjusted EBITDA. Second-quarter Operating Cash Flow was $443 million and Free Cash Flow was $292 million. During the quarter, IQVIA repurchased $607 million of common stock, bringing first-half repurchases to $1,032 million, with $1,981 million of authorization remaining as of June 30, 2025. The filing states that the information is furnished and not deemed filed under Section 18 of the Exchange Act.

Jul 22, 2025 8-K

IQVIA Holdings 8-K Report, Material Agreement (Jun 4, 2025)

IQVIA Holdings Inc. (IQV) disclosed in this Form 8-K that its wholly owned subsidiary, IQVIA Inc. (the "Issuer"), completed the issuance and sale of $2.0 billion in gross proceeds of 6.250% senior notes due 2032 on June 4, 2025. The notes are unsecured obligations of the Issuer, mature on June 1, 2032, and pay interest semi-annually on June 1 and December 1, beginning December 1, 2025. The notes were issued under an Indenture dated June 4, 2025, with U.S. Bank Trust Company, National Association, as trustee, and certain Issuer subsidiaries as guarantors. Net proceeds will be used to repay existing borrowings under the Issuer's revolving credit facility and to pay fees and expenses of the offering, with any excess used for general corporate purposes. The filing states that the Issuer may redeem the notes before maturity subject to a customary make-whole premium at any time before June 1, 2028 (subject to a customary "equity claw" right), and thereafter at a redemption premium declining from 3.125% to 0.000%. The filing is a debt financing event that refinances revolving credit borrowings with fixed-rate longer-dated notes. Item 1.01 and Item 2.03 describe the transaction, and Item 9.01 lists the Indenture (Exhibit 4.1) and the cover page interactive data file (Exhibit 104).

Jun 4, 2025 8-K

IQVIA Holdings 8-K Report, Corporate Update (Jun 2, 2025)

IQVIA Holdings Inc. (IQV) announced on June 2, 2025 that its wholly owned subsidiary, IQVIA Inc. (the "Issuer"), intends to raise $2,000,000,000 in gross proceeds through an offering of senior notes due 2032. The Issuer entered into a purchase agreement on the same day for the sale of $2.00 billion in aggregate principal amount of these notes, which bear interest at 6.250% per annum. Closing is expected on or about June 4, 2025, subject to customary closing conditions. The company stated that net proceeds will be used to repay existing borrowings under the Issuer's revolving credit facility and to pay fees and expenses related to the offering, with any excess used for other general corporate purposes. For investors, the transaction is primarily a refinancing: it replaces revolving credit borrowings with fixed-rate senior notes maturing June 1, 2032, and the filing does not state any change in total debt beyond the stated use of proceeds. The notes are being offered under Rule 144A to qualified institutional buyers in the United States and under Regulation S outside the United States, and have not been registered under the Securities Act. The filing's forward-looking statements caution that the offering may fail to close and that market conditions could cause results to differ materially.

Jun 2, 2025 8-K

Shareholder MattersCorporate ChangesExhibits & Filings

IQVIA Holdings 8-K Report, Financial Results (May 6, 2025)

IQVIA Holdings Inc. reported first-quarter 2025 results on May 6, 2025, with revenue of $3,829 million, up 2.5 percent on a reported basis and 3.5 percent at constant currency. GAAP net income was $249 million and GAAP diluted earnings per share were $1.40, while Adjusted EBITDA was $883 million, up 2.4 percent year-over-year, and Adjusted Diluted Earnings per Share were $2.70, up 6.3 percent. Technology & Analytics Solutions (TAS) was the standout segment, with revenue of $1,546 million growing 7.6 percent at constant currency. Management attributed softness in clinical trial business to delayed customer decision-making on new programs amid macroeconomic and industry uncertainty, though R&DS forward-looking indicators such as qualified pipeline, RFP flow and backlog continued to grow. R&DS revenue of $2,102 million rose 0.3 percent on a reported basis, and contracted backlog reached $31.5 billion, up 4.8 percent year-over-year. First-quarter R&DS net new bookings were $2.1 billion, for a trailing-twelve-month book-to-bill ratio of 1.14x. Contract Sales & Medical Solutions revenue declined 4.2 percent on a reported basis to $181 million. The company raised full-year 2025 revenue guidance to between $16,000 million and $16,400 million, reflecting favorable foreign currency movements, and reaffirmed Adjusted EBITDA guidance of $3,765 million to $3,885 million and Adjusted Diluted EPS guidance of $11.70 to $12.10. Balance sheet metrics show debt of $14,330 million, net debt of $12,590 million and a Net Leverage Ratio of 3.40x. The company repurchased $425 million of common stock during the quarter and had $2,588 million of authorization remaining.

May 6, 2025 8-K

IQVIA Holdings 8-K Report, Bylaw Amendment (Apr 24, 2025)

On April 24, 2025, IQVIA Holdings Inc. held its 2025 Annual Meeting of Stockholders, where shareholders approved an amendment to the Amended and Restated Certificate of Incorporation. The amendment provides for exculpation from liability for certain officers to the fullest extent permitted by Delaware law and removes obsolete provisions tied to the company's previous classified board structure. The amended charter became effective upon filing with the Delaware Secretary of State on April 24, 2025. At the meeting, all nine director nominees were elected to one-year terms by majority vote. Stockholders also approved, on an advisory basis, the 2024 compensation of the named executive officers, though with a notably larger Against count (26,212,786) than For count (125,637,769) among the votes cast. PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2025, with 145,558,841 votes for and 14,744,090 against. A non-binding stockholder proposal concerning special stockholder meetings did not pass, receiving 66,155,724 votes for and 86,013,439 against. The record date was February 24, 2025, with 176,315,036 shares of common stock outstanding and entitled to vote on all matters.

Apr 24, 2025 8-K

Material AgreementsFinancial EventsExhibits & Filings

IQVIA Holdings 8-K Report, Material Agreement (Mar 10, 2025)

IQVIA Holdings Inc. (IQV) disclosed in this Form 8-K filed March 10, 2025 that it entered into Amendment No. 4 to its Fifth Amended and Restated Credit Agreement on that date. The amendment creates a new class of term B dollar loans used to refinance its Term B-4 Dollar Loans, lowering the interest rate on those borrowings from SOFR plus an applicable margin of 2.00% per annum to SOFR plus 1.75% per annum. The new loans also fund the repayment in full of its Term B-2 Euro Loans. The transaction is a debt refinancing rather than new borrowing for growth or acquisitions. The filing describes the change as a reduction in the margin on the refinanced dollar term loans, along with the retirement of the Euro-denominated term loans. The filing does not include financial results, guidance, or other operating information. The amendment is filed as Exhibit 10.1, which names IQVIA Inc., IQVIA Holdings Inc., IQVIA RDS Inc., other guarantors, Bank of America, N.A. as administrative and collateral agent, and the lending parties. Item 2.03 incorporates the Item 1.01 disclosure by reference.

Mar 10, 2025 8-K

IQVIA Holdings 8-K Report, Financial Results (Feb 6, 2025)

IQVIA Holdings Inc. filed this Form 8-K under Item 2.02 to furnish a press release reporting fourth-quarter and full-year 2024 results. For the fourth quarter, revenue was $3,958 million, up 2.3 percent on a reported basis and 3.0 percent at constant currency. GAAP net income was $437 million and GAAP diluted EPS was $2.42, while Adjusted Diluted EPS was $3.12 and Adjusted EBITDA was $996 million. For the full year, revenue was $15,405 million, GAAP net income was $1,373 million, and Adjusted Diluted EPS was $11.13, up 9.1 percent. Operating cash flow reached $2,716 million and free cash flow reached $2,114 million, up 26 percent and 41 percent year-over-year, respectively. The R&D Solutions segment booked over $2.5 billion in the quarter, a book-to-bill ratio of 1.20x, and ended the year with contracted backlog of $31.1 billion. The Technology & Analytics Solutions segment grew 9.5 percent at constant currency in the quarter and reached $6,160 million for the full year. Net debt was $12,281 million, and the Net Leverage Ratio was 3.33x trailing twelve-month Adjusted EBITDA. The company repurchased $1,350 million of stock in 2024 and, on February 5, 2025, increased its repurchase authorization by $2,000 million to a total of $3,013 million. Management reaffirmed its 2025 outlook, including revenue guidance of $15,725 million to $16,125 million, Adjusted EBITDA of $3,765 million to $3,885 million, and Adjusted Diluted EPS of $11.70 to $12.10, with constant-currency ex-COVID revenue growth of 4 to 7 percent.

Feb 6, 2025 8-K

IQVIA Holdings 8-K Report, Financial Results (Oct 31, 2024)

IQVIA Holdings Inc. filed this Form 8-K on October 31, 2024 to furnish its press release reporting third-quarter 2024 results, along with an update to full-year 2024 guidance and the announcement of an Investor Day on December 10, 2024. Third-quarter revenue was $3,896 million, up 4.3 percent on a reported basis, with GAAP Net Income of $285 million, Adjusted EBITDA of $939 million, and GAAP Diluted EPS of $1.55 versus Adjusted Diluted EPS of $2.84. Technology & Analytics Solutions (TAS) revenue of $1,554 million grew 8.6 percent reported, while R&D Solutions (R&DS) revenue of $2,162 million rose 1.9 percent reported. R&DS contracted backlog reached $31.1 billion, up 8.0 percent year-over-year, and the third-quarter book-to-bill ratio was 1.06x, which includes a large program cancellation due to drug futility. Management lowered full-year 2024 guidance to revenue of $15,350 million to $15,400 million, Adjusted EBITDA of $3,675 million to $3,700 million, and Adjusted Diluted EPS of $11.10 to $11.20. The company attributed the update to delays in two fast-burning mega trials caused by client-related short-term logistical challenges, which are now expected to ramp in the second half of 2025. Operating cash flow for the first nine months was $1,831 million and free cash flow was $1,393 million, while net debt stood at $11,940 million, a Net Leverage Ratio of 3.27x trailing twelve-month Adjusted EBITDA. The company repurchased $200 million of common stock in the third quarter and had $2,163 million of authorization remaining as of September 30, 2024. Chairman and CEO Ari Bousbib stated that margins expanded, free cash flow was strong, and TAS growth accelerated, while R&DS fundamentals remain solid based on RFP flow, qualified pipeline growth, backlog growth, and next-twelve-month revenue from backlog.

Oct 31, 2024 8-K

IQVIA Holdings 8-K Report, Financial Results (Jul 22, 2024)

IQVIA Holdings Inc. (IQV) furnished an 8-K on July 22, 2024 under Item 2.02 (Results of Operations and Financial Condition), attaching a press release (Exhibit 99.1) reporting results for the second quarter ended June 30, 2024. Second-quarter revenue was $3,814 million, up 2.3 percent on a reported basis and 3.5 percent at constant currency. GAAP net income was $363 million, or $1.97 per diluted share, and Adjusted EBITDA was $887 million. Adjusted diluted EPS was $2.64. Management said the quarter came in at the high end of guidance, driven mainly by better-than-expected Technology & Analytics Solutions (TAS) performance. R&D Solutions (R&DS) showed continued strength: quarterly bookings were $2.7 billion, a book-to-bill ratio of 1.27x, and contracted backlog reached $30.6 billion, up 7.7 percent reported and 8.1 percent at constant currency year-over-year. The company expects approximately $7.8 billion of that backlog to convert to revenue in the next twelve months. Contract Sales & Medical Solutions revenue of $172 million declined 2.3 percent on a reported basis. Balance sheet metrics show total debt of $13,258 million and net debt of $11,713 million as of June 30, 2024, with a Net Leverage Ratio of 3.25x trailing twelve-month Adjusted EBITDA. Second-quarter operating cash flow was $588 million and free cash flow was $445 million. The company updated full-year 2024 guidance: revenue of $15,425 million to $15,525 million, Adjusted EBITDA of $3,705 million to $3,765 million, and Adjusted Diluted EPS of $11.10 to $11.30, assuming foreign exchange rates as of July 18, 2024.

Jul 22, 2024 8-K

Leadership Changes

IQVIA Holdings 8-K Report, Executive Changes (May 10, 2024)

IQVIA Holdings Inc. (IQV) filed a Current Report on Form 8-K dated May 10, 2024, reporting an event from May 6, 2024. Under Item 5.02 (Departure of Directors or Certain Officers; Compensatory Arrangements of Certain Officers), the Company announced that Kevin C. Knightly, President, Corporate Strategy and Enterprise Networks, will transition from his current role effective May 15, 2024. Following the transition, Mr. Knightly will become a senior advisor to the Chief Executive Officer. The filing states that he will receive compensation commensurate with this new role, but it does not disclose the amount or terms of that compensation. The filing is a limited leadership notice. It contains no financial results, guidance, or other financial metrics, so the change is primarily a management and governance development for investors to note.

May 10, 2024 8-K

IQVIA Holdings 8-K Report, Financial Results (May 2, 2024)

IQVIA Holdings Inc. reported first-quarter 2024 results in a press release dated May 2, 2024, furnished as Exhibit 99.1 under Item 2.02. Revenue was $3,737 million, up 2.3 percent on a reported basis and 2.9 percent at constant currency, compared with the first quarter of 2023. GAAP net income was $288 million and GAAP diluted EPS was $1.56, while Adjusted Net Income was $468 million, Adjusted Diluted EPS was $2.54, and Adjusted EBITDA was $862 million, up 1.3 percent year-over-year. By segment, Technology & Analytics Solutions revenue was $1,453 million, up 0.6 percent reported, and Research & Development Solutions revenue was $2,095 million, up 3.4 percent reported. Contract Sales & Medical Solutions revenue was $189 million, up 3.8 percent reported. R&DS contracted backlog reached $30.1 billion, up 7.9 percent year-over-year, and the first-quarter book-to-bill ratio was 1.23x, including the cancellation of a large central nervous system program. The company expects approximately $7.7 billion of backlog to convert to revenue in the next twelve months. The company reaffirmed full-year 2024 guidance: revenue of $15,325 million to $15,575 million on a reported basis (growth of 2.3 to 3.9 percent), Adjusted EBITDA of $3,700 million to $3,800 million, and Adjusted Diluted EPS of $10.95 to $11.25. Net debt was $12,092 million at March 31, 2024, with a Net Leverage Ratio of 3.38x trailing twelve-month Adjusted EBITDA, and first-quarter Free Cash Flow was $377 million.

May 2, 2024 8-K

Shareholder Matters

IQVIA Holdings 8-K Report, Shareholder Vote Results (Apr 17, 2024)

IQVIA Holdings Inc. filed this Form 8-K under Item 5.07 to report the voting results of its 2024 Annual Meeting of Stockholders, held April 16, 2024. As of the February 20, 2024 record date, 182,013,590 shares of common stock were outstanding and entitled to vote. Stockholders re-elected all six board nominees (Ari Bousbib, Carol J. Burt, Colleen A. Goggins, John M. Leonard, MD, Todd B. Sisitsky and Sheila A. Stamps) to one-year terms. Sisitsky drew the weakest support, with 129,897,117 votes for and 30,538,472 against, while the other nominees received far more votes for than against. Stockholders approved, on an advisory basis, the 2023 compensation of the named executive officers, with 134,057,263 votes for and 26,075,678 against. A non-binding stockholder proposal concerning political spending was not approved, receiving 21,082,315 votes for and 137,953,664 against. Stockholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2024, with 152,245,315 votes for and 14,801,559 against. For investors, the filing shows broad support for the board slate, the executive pay program and the auditor, with the main dissent concentrated in the director vote for Sisitsky and the stockholder proposal on political spending. The 8-K reports only the meeting outcomes and does not discuss financial performance.

Apr 17, 2024 8-K

Material AgreementsFinancial EventsOther Events+1

IQVIA Holdings 8-K Report, Financial Results (Feb 14, 2024)

IQVIA Holdings Inc. furnished an 8-K on February 14, 2024 (Item 2.02) attaching a press release reporting fourth-quarter and full-year 2023 results and issuing full-year 2024 guidance. For Q4 2023, revenue was $3,868 million (up 3.5 percent reported), GAAP net income was $469 million, and Adjusted EBITDA was $966 million. For full-year 2023, revenue was $14,984 million (up 4.0 percent reported), GAAP net income was $1,358 million, GAAP diluted EPS was $7.29, Adjusted Diluted EPS was $10.20 (up 0.4 percent), and Adjusted EBITDA was $3,569 million (up 6.7 percent). R&DS contracted backlog reached $29.7 billion, growing 9.2 percent year-over-year, and the fourth-quarter book-to-bill ratio was 1.31x. The company ended 2023 with cash of $1,376 million, debt of $13,673 million and net debt of $12,297 million, a Net Leverage Ratio of 3.45x. Operating cash flow for the full year was $2,149 million and free cash flow was $1,500 million. The company refinanced approximately $2.75 billion of near-term maturities in the fourth quarter, extending maturities to 2029 and 2031 at an average fixed rate below 4.9 percent after swaps, and over 80 percent of its debt is now fixed-rate. Share repurchases totaled $992 million for the year, with $2,363 million of authorization remaining. For 2024, IQVIA guided to revenue of $15,400 million to $15,650 million, Adjusted EBITDA of $3,700 million to $3,800 million, and Adjusted Diluted EPS of $10.95 to $11.25. The revenue outlook assumes roughly $300 million of COVID-related revenue step-down, about 50 basis points of foreign exchange headwind, and about 100 basis points of contribution from acquisitions. Management described the 2023 results as solid in a challenging macro environment, citing strong clinical demand and a 1.31 book-to-bill ratio for the quarter.

Feb 14, 2024 8-K

IQVIA Holdings 8-K Report, Material Agreement (Nov 28, 2023)

IQVIA Holdings Inc. (IQV) disclosed on November 28, 2023 that its wholly owned subsidiary, IQVIA Inc. (the Issuer or Borrower), completed the issuance and sale of $1.25 billion in gross proceeds of 6.250% senior secured notes due 2029. The Notes are secured obligations of the Issuer, mature on February 1, 2029, pay interest semi-annually on February 1 and August 1 beginning February 1, 2024, and are issued under an Indenture with U.S. Bank Trust Company, National Association as trustee and collateral agent, with the Company and certain subsidiaries as guarantors. The Issuer may redeem the Notes before January 1, 2029 subject to a customary make-whole premium, and on or after that date at 100% of principal plus accrued and unpaid interest. Concurrently, the Company entered into Amendment No. 3 to its Fifth Amended and Restated Credit Agreement, under which it borrowed $1.5 billion in incremental Term B-4 Dollar Loans. The net proceeds of the Notes and the Term B-4 loans will be used to repay the Euro-denominated term B loan due March 2024, the U.S. dollar term B loans due January 2025 and June 2025, and to pay related fees and expenses. Under Item 8.01, the filing states that the Company entered into two cross-currency swap agreements (November 15 and November 17, 2023) that effectively convert the Notes and Term B-4 Dollar Loans into euro-denominated borrowings at prevailing euro rates, with effective net borrowing rates of 4.8555% for the Notes and 4.9015% for the Term B-4 Dollar Loans.

Nov 28, 2023 8-K

IQVIA Holdings 8-K Report, Corporate Update (Nov 15, 2023)

On November 14, 2023, IQVIA Holdings Inc. announced that its wholly owned subsidiary, IQVIA Inc., intended to raise $500 million through senior secured notes due 2029 and to refinance part of its existing debt. The same day, the Issuer entered into a purchase agreement for $1.25 billion of senior secured notes due 2029 bearing interest at 6.250% per annum. The closing is expected on or about November 28, 2023, subject to customary closing conditions. On November 15, 2023, the company announced the pricing of the offering, which was upsized due to strong demand to $1.25 billion in aggregate principal amount, including an additional $750 million. Concurrently, the Issuer intends to amend its senior secured credit facilities to add a new term B loan due 2031 of approximately $1.25 billion. Proceeds from the notes and the new term loan are expected to repay certain outstanding term loans due in 2024 and 2025, and to pay related fees and expenses. In connection with the pricing, the company entered into a cross-currency swap agreement to convert $1.25 billion of the notes into a euro-denominated borrowing, with an effective net borrowing rate of approximately 4.8555%. The company also intends to enter into additional cross-currency swaps to hedge dollar-denominated debt created by the new term loan, though there is no assurance it will do so. The filing states that the Credit Agreement Amendment and the new term loan are not conditioned on the notes offering, and the notes offering is not conditioned on them.

Nov 15, 2023 8-K

IQVIA Holdings 8-K Report, Financial Results (Nov 1, 2023)

IQVIA Holdings Inc. (NYSE: IQV) reported third-quarter 2023 results on November 1, 2023, via a press release furnished as Exhibit 99.1 under Item 2.02. Revenue was $3,736 million, up 4.9 percent on a reported basis and 4.1 percent at constant currency. GAAP net income was $303 million, GAAP diluted EPS was $1.63, Adjusted Net Income was $462 million, and Adjusted Diluted EPS was $2.49. Adjusted EBITDA was $888 million, up 9.1 percent year-over-year. R&DS, the largest segment, posted revenue of $2,122 million, up 7.2 percent on a reported basis, a quarterly book-to-bill ratio of 1.24x, and contracted backlog of $28.8 billion, up 11.7 percent year-over-year. TAS revenue of $1,431 million grew 2.2 percent, while CSMS revenue was flat at $183 million. The company lowered its full-year 2023 revenue guidance to $14,885 million to $14,920 million, citing slower growth in TAS and the stronger U.S. dollar. Adjusted EBITDA guidance was narrowed to $3,560 million to $3,570 million, and Adjusted Diluted EPS guidance was set at $10.16 to $10.23. For the fourth quarter, the company expects revenue of $3,769 million to $3,804 million and Adjusted Diluted EPS of $2.79 to $2.86. Balance sheet metrics were mixed. Cash and equivalents were $1,224 million against debt of $13,631 million, giving net debt of $12,407 million and a Net Leverage Ratio of 3.52x. Nine-month operating cash flow was $1,402 million and free cash flow was $932 million. The company repurchased $763 million of stock year-to-date and had $2,592 million of authorization remaining.

Nov 1, 2023 8-K

IQVIA Holdings 8-K Report, Executive Changes (Sep 26, 2023)

IQVIA Holdings Inc. (IQV) filed this Form 8-K on September 26, 2023 to report a leadership change in its Research & Development Solutions (R&DS) business unit. The company appointed Richard Staub III as President of R&DS, effective September 25, 2023. Staub previously led the R&DS business unit from 2016 to 2022 and, most recently, served as a senior advisor to the Company's Chairman and CEO, where he had responsibility for key customer relationships and guided the business's strategic direction. He brings thirty-four years of relevant industry experience. The filing also discloses the departure of Costa Panagos, who had been President of R&DS. Panagos informed the Company on September 24, 2023 of his intention to leave, and his last day was September 25, 2023. Per his Confidentiality and Restrictive Covenants Agreement, he is subject to noncompetition and nonsolicitation covenants for 12 months following the termination of his employment. The press release announcing both changes, dated September 25, 2023, is furnished as Exhibit 99.1 under Item 7.01. For investors, the key takeaway is a return of an experienced executive to lead the R&DS segment, with the press release describing his prior tenure as including record backlog, industry-leading book-to-bill ratios and significantly increased R&DS revenues. The filing itself does not provide financial results or guidance tied to this change.

Sep 26, 2023 8-K

Material AgreementsFinancial EventsExhibits & Filings

IQVIA Holdings 8-K Report, Financial Results (Aug 1, 2023)

IQVIA Holdings Inc. (IQV) reported second-quarter 2023 results on August 1, 2023, as furnished in Exhibit 99.1. Revenue was $3,728 million, up 5.3 percent on a reported basis and 5.5 percent at constant currency. GAAP Net Income was $297 million and GAAP Diluted Earnings per Share was $1.59, while Adjusted Diluted Earnings per Share was $2.43, down 0.4 percent year-over-year. R&D Solutions (R&DS) contracted backlog reached $28.4 billion, growing 11.1 percent year-over-year, with a second-quarter book-to-bill ratio of 1.28x. CEO Ari Bousbib stated that commercial-side clients remain cautious and spending has not yet accelerated, while the clinical business is performing consistently with expectations. The company updated its full-year 2023 guidance, with revenue now expected between $15,050 million and $15,175 million, representing 4.4 to 5.3 percent reported growth. Adjusted EBITDA guidance is $3,600 million to $3,635 million, and Adjusted Diluted EPS guidance is $10.20 to $10.45. The company noted that step-up in interest rates and an increase in the UK corporate tax rate reduce year-over-year Adjusted EPS growth by approximately 12 percentage points. Third-quarter revenue is guided to $3,760 million to $3,810 million. Balance sheet metrics showed total debt of $13,777 million, net debt of $12,395 million, and a Net Leverage Ratio of 3.59x. The company repurchased $490 million of stock in the second quarter and $619 million year-to-date. On July 31, 2023, the board increased the repurchase authorization by $2 billion, bringing total remaining authorization to $2,736 million.

Aug 1, 2023 8-K

IQVIA Holdings 8-K Report, Material Agreement (May 23, 2023)

IQVIA Inc., a wholly owned subsidiary of IQVIA Holdings Inc., completed on May 23, 2023 the issuance and sale of two series of notes: $750,000,000 in gross proceeds of 5.700% senior secured notes due May 15, 2028, and $500,000,000 in gross proceeds of 6.500% senior notes due May 15, 2030. Both series were issued under separate indentures dated May 23, 2023, with U.S. Bank Trust Company, National Association, as trustee. The Senior Secured Notes are secured obligations of the Issuer, while the Senior Notes are unsecured. Interest on both series is payable semi-annually on May 15 and November 15, beginning November 15, 2023. The filing states that net proceeds will be used to repay existing borrowings under the Issuer's revolving credit facility and to pay fees and expenses related to the offering. The transaction therefore refinances revolving credit facility debt with longer-dated fixed-rate notes. The Company and certain subsidiaries of the Issuer are named as guarantors under the indentures. The Senior Secured Notes may be redeemed before April 15, 2028 subject to a customary make-whole premium, and at 100% of principal plus accrued interest thereafter. The Senior Notes may be redeemed before their maturity subject to a make-whole premium, with an equity claw redemption right available before May 15, 2026, and thereafter at a redemption premium declining from 3.250% to 0.000%. The full terms are set out in Exhibits 4.1 and 4.2, the indentures.

May 23, 2023 8-K

IQVIA Holdings 8-K Report, Corporate Update (May 19, 2023)

IQVIA Holdings Inc. (NYSE: IQV) disclosed on May 19, 2023 that its wholly owned subsidiary, IQVIA Inc. (the "Issuer"), is raising capital through a notes offering. On May 18, 2023, the Issuer entered into a purchase agreement for $750,000,000 of senior secured notes due 2028 bearing interest at 5.700% per annum and $500,000,000 of senior notes due 2030 bearing interest at 6.500% per annum. The company also announced an additional $250,000,000 of senior secured notes due 2028 as part of the pricing, bringing total gross proceeds to $1,250,000,000. The offering was upsized, which the filing attributes to strong demand. Proceeds will be used to repay existing borrowings under the Issuer's revolving credit facility and to pay fees and expenses related to the offering. The filing states the offering is expected to close on or about May 23, 2023, subject to customary closing conditions. The notes have not been registered under the Securities Act and are being offered to qualified institutional buyers under Rule 144A and to non-U.S. investors under Regulation S. For investors, the filing shows IQVIA refinancing existing revolver debt with longer-dated fixed-rate notes, with the senior secured tranche maturing May 15, 2028 and the senior notes maturing May 15, 2030. Interest on both tranches is payable semi-annually on May 15 and November 15, beginning November 15, 2023. The filing does not provide additional financial results or covenant details.

May 19, 2023 8-K

Shareholder MattersCorporate ChangesExhibits & Filings

IQVIA Holdings 8-K Report, Financial Results (Apr 27, 2023)

IQVIA Holdings Inc. (NYSE: IQV) furnished an Item 2.02 Form 8-K on April 27, 2023 attaching a press release reporting first-quarter 2023 results for the quarter ended March 31, 2023. Revenue was $3,652 million, up 2.4 percent on a reported basis and 4.7 percent at constant currency versus the prior year. GAAP net income was $289 million and GAAP diluted EPS was $1.53, compared with $325 million and $1.68 in the first quarter of 2022. Adjusted EBITDA was $851 million and Adjusted Diluted EPS was $2.45. By segment, R&D Solutions revenue was $2,026 million (up 4.8 percent reported), Technology & Analytics Solutions revenue was $1,444 million (up 0.3 percent reported), and Contract Sales & Medical Solutions revenue was $182 million (down 6.7 percent reported). Bookings and backlog were solid. R&D Solutions bookings were $2.6 billion in the quarter, a book-to-bill ratio of 1.28x, and contracted backlog reached $27.9 billion, growing 10.1 percent year-over-year and 11.3 percent at constant currency. The company expects about $7.3 billion of that backlog to convert to revenue over the next twelve months. Management cited healthy industry demand and record RFP flow, while noting some customer caution in discretionary spending. Balance sheet and guidance: cash and cash equivalents were $1,494 million, debt was $13,176 million, and net debt was $11,682 million, a Net Leverage Ratio of 3.45x trailing twelve-month Adjusted EBITDA. Operating cash flow was $417 million and free cash flow was $253 million. IQVIA repurchased $129 million of stock and had $1,226 million of authorization remaining. The company reaffirmed full-year 2023 guidance: revenue of $15,150 million to $15,400 million, Adjusted EBITDA of $3,625 million to $3,695 million, and Adjusted Diluted EPS of $10.26 to $10.56.

Apr 27, 2023 8-K

IQVIA Holdings 8-K Report, Bylaw Amendment (Apr 18, 2023)

IQVIA Holdings Inc. held its 2023 Annual Meeting of Stockholders on April 18, 2023, where stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation granting holders of at least 25% of outstanding common stock the right to request a special meeting of stockholders (a "Special Meeting Right"). The amended Charter and corresponding Amended and Restated Bylaws both became effective on April 18, 2023. The Board had previously approved the Bylaws amendment, subject to stockholder approval of the proposal. At the meeting, 186,141,208 shares of common stock were outstanding and entitled to vote as of the February 17, 2023 record date. All three director nominees, Carol J. Burt, Colleen A. Goggins and Sheila A. Stamps, were elected to one-year terms, and PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2023. Stockholders also approved the Special Meeting Right charter amendment, with 141,139,003 votes for, 5,721,441 against and 12,444,869 abstaining. Stockholders did not approve the advisory say-on-pay vote, which received 126,672,483 for and 32,526,896 against. The advisory stockholder proposal concerning special stockholder meetings received 77,091,008 for and 81,643,308 against, and the advisory proposal for separate Chairman and CEO roles received 54,282,603 for and 104,922,150 against.

Apr 18, 2023 8-K

Material AgreementsFinancial EventsExhibits & Filings

IQVIA Holdings 8-K Report, Material Agreement (Apr 18, 2023)

IQVIA Holdings Inc. filed this Form 8-K to report two related events under Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation). On April 17, 2023, IQVIA Holdings Inc. entered into Amendment No. 2 to its Fifth Amended and Restated Credit Agreement. The amendment increases the revolving credit commitments under the existing revolving credit facility to $2.0 billion. The amendment also replaces the London Interbank Offered Rate (LIBOR) with the Secured Overnight Funding Rate (SOFR) for the revolving credit facility and for a portion of the outstanding term loans. The agreement is administered by Bank of America, N.A. as administrative and collateral agent, and involves IQVIA Inc., IQVIA Holdings Inc., IQVIA RDS Inc., IQVIA AG, IQVIA Japan K.K., other guarantors, and the lenders party to it. For investors, the key takeaways are the larger committed revolving liquidity of $2.0 billion and the benchmark rate transition from LIBOR to SOFR on part of the borrowings. The filing does not state the amounts drawn, pricing changes, or maturity terms, and it refers to the full terms in Exhibit 10.1.

Apr 18, 2023 8-K

Corporate ChangesExhibits & Filings

IQVIA Holdings 8-K Report, Bylaw Amendment (Feb 13, 2023)

IQVIA Holdings Inc. filed this Form 8-K on February 13, 2023 to report an amendment to its Amended and Restated Bylaws, effective the same day. The Board of Directors approved the changes, which the filing says were made to implement a majority voting standard in uncontested director elections based on stockholder feedback, in a form consistent with approximately 99% of S&P 500 companies that have adopted a majority voting standard. The amendments also update the advance notice provisions to account for recent SEC rules on the use of universal proxies, and reflect recent amendments to the Delaware General Corporation Law regarding information provided at stockholder meetings. The filing states that the revisions also include technical, conforming, and clarifying changes. The filing contains no financial results, financial statement figures, or quantified financial impact. Its significance for investors lies in governance: the revised bylaws change how directors are elected in uncontested races and how stockholders can nominate directors, and the complete text is filed as Exhibit 3.1.

Feb 13, 2023 8-K

IQVIA Holdings 8-K Report, Financial Results (Feb 10, 2023)

IQVIA Holdings Inc. (NYSE: IQV) reported preliminary, unaudited fourth-quarter and full-year 2022 results and issued full-year 2023 guidance in a press release dated February 10, 2023, furnished as Exhibit 99.1. Fourth-quarter revenue was $3,739 million, up 2.8 percent on a reported basis and 7.0 percent at constant currency, while GAAP net income fell to $227 million, down 28.6 percent year-over-year. Adjusted Diluted EPS rose 9.0 percent to $2.78, and Adjusted EBITDA reached $920 million, up 11.1 percent. For full-year 2022, revenue was $14,410 million, up 3.9 percent reported and 7.8 percent at constant currency, with GAAP diluted EPS of $5.72 and Adjusted Diluted EPS of $10.16. R&D Solutions contracted backlog reached $27.2 billion, up 9.6 percent year-over-year and 11.6 percent at constant currency, and fourth-quarter bookings exceeded $3.1 billion with a 1.51x book-to-bill ratio including reimbursed expenses. Net debt was $11,531 million at year-end, with a Net Leverage Ratio of 3.45x trailing Adjusted EBITDA. Full-year share repurchases totaled $1,168 million, leaving $1,355 million of authorization remaining. For 2023, IQVIA guided revenue of $15,150 million to $15,400 million (5.1 to 6.9 percent reported growth), Adjusted EBITDA of $3,625 million to $3,695 million, and Adjusted Diluted EPS of $10.26 to $10.56. The company noted that step-up in interest rates and a UK corporate tax rate increase reduce Adjusted EPS growth by about 10 percentage points, and it assumes roughly $600 million of COVID-related revenue step-down versus 2022.

Feb 10, 2023 8-K

IQVIA Holdings 8-K Report, Financial Results (Oct 26, 2022)

IQVIA Holdings Inc. filed this Form 8-K under Item 2.02 (Results of Operations and Financial Condition) to furnish a press release dated October 26, 2022, announcing results for the third quarter ended September 30, 2022. The information is furnished, not filed, for purposes of Section 18 of the Exchange Act. Third-quarter revenue was $3,562 million, up 5.0 percent on a reported basis and 10.5 percent at constant currency. GAAP Net Income was $283 million (up 8.4 percent) and GAAP Diluted EPS was $1.49 (up 11.2 percent). Adjusted EBITDA was $814 million (up 11.8 percent) and Adjusted Diluted EPS was $2.48 (up 14.3 percent). Bookings and backlog were a key highlight. R&D Solutions quarterly bookings exceeded $2.5 billion, and excluding pass-throughs reached a historic high of over $2.0 billion, a services book-to-bill ratio of 1.39x. R&DS contracted backlog was $25.8 billion, up 5.4 percent reported and 9.4 percent excluding foreign exchange. For the first nine months of 2022, revenue was $10,671 million and GAAP Diluted EPS was $4.52. The company updated full-year 2022 guidance, now expecting revenue of $14,325 million to $14,425 million (3.2 to 4.0 percent reported growth; 7.4 to 8.2 percent at constant currency), reflecting primarily a stronger U.S. dollar and minor trial delivery delays. Adjusted EBITDA guidance is $3,330 million to $3,360 million, and Adjusted Diluted EPS guidance is $10.10 to $10.20, with the midpoint raised by 5 cents. Net debt was $11,120 million at September 30, 2022, a Net Leverage Ratio of 3.4x trailing twelve-month Adjusted EBITDA.

Oct 26, 2022 8-K

Leadership Changes

IQVIA Holdings 8-K Report, Executive Changes (Oct 3, 2022)

IQVIA Holdings Inc. filed this Current Report on Form 8-K, dated October 3, 2022 (event date October 2, 2022), to disclose a board change. The filing states that Ronald A. Rittenmeyer resigned from the Company's board of directors and as chairman of the Leadership Development and Compensation Committee (LDCC), effective October 2, 2022, citing personal health reasons. The Company states that the resignation was a personal decision and was not due to any disagreement with IQVIA on any matter relating to its operations, policies or practices. The filing is limited to Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers) and contains no financial results, guidance, or other operating information. For investors, the filing is a governance notice. The filing does not name a successor or interim chair of the LDCC, and it does not describe any financial impact.

Oct 3, 2022 8-K

Leadership Changes

IQVIA Holdings 8-K Report, Executive Changes (Jul 29, 2022)

IQVIA Holdings Inc. filed this Form 8-K under Item 5.02 to announce the appointment of Keriann Cherofsky as Senior Vice President, Corporate Controller and principal accounting officer, effective August 1, 2022. Ms. Cherofsky, age 38, has 16 years of relevant experience, including service as the Company's Assistant Controller from March 2019 to August 2022, Executive Director leading SEC reporting at JPMorgan Chase & Co. from November 2015 to March 2019, and various positions at PricewaterhouseCoopers LLP beginning in September 2006, most recently as Senior Manager. Under her offer, Ms. Cherofsky will receive an annual base salary of $335,000, an annual incentive target of 50% of base salary under the Company's annual incentive plan, and a long-term incentive award with an aggregate grant date fair value of $285,000. The award comprises performance shares earned over January 1, 2022 through December 31, 2024, plus stock appreciation rights and restricted stock units that each vest ratably over three years, all under the 2017 Incentive and Stock Award Plan. She will also remain eligible for the Company's standard U.S. benefits plans. The filing also discloses that Emmanuel Korakis, Senior Vice President, Corporate Controller and Treasurer, notified the Company on July 25, 2022 that he is leaving to become Chief Financial Officer of Presidio, Inc., with his last day set for July 31, 2022. The transition therefore moves the controller role from Mr. Korakis to Ms. Cherofsky, who takes over the principal accounting officer function.

Jul 29, 2022 8-K

Material AgreementsFinancial EventsExhibits & Filings

IQVIA Holdings 8-K Report, Financial Results (Jul 21, 2022)

IQVIA Holdings Inc. (NYSE: IQV) furnished an 8-K under Item 2.02 on July 21, 2022, attaching a press release reporting results for the second quarter ended June 30, 2022. Second-quarter revenue was $3,541 million, up 3.0 percent on a reported basis and 7.1 percent at constant currency. GAAP net income was $256 million, up 46.3 percent year-over-year, and GAAP diluted EPS was $1.34. Adjusted EBITDA was $800 million, up 10.8 percent, and Adjusted Diluted EPS was $2.44, up 14.6 percent. R&DS quarterly bookings were described as over $2.6 billion, and R&DS contracted backlog reached $25.6 billion, up 7.1 percent at actual currency. Balance sheet and cash generation were also reported. As of June 30, 2022, net debt was $11,339 million, and the Net Leverage Ratio was 3.6x trailing twelve-month Adjusted EBITDA. Second-quarter Free Cash Flow was $168 million, and the company repurchased $590 million of common stock in the quarter, bringing year-to-date repurchases to $993 million. Remaining share repurchase authorization was $1,530 million as of June 30, 2022. For 2022, the company kept its low-to-mid teens organic constant-currency revenue growth outlook (excluding COVID-related work) unchanged, but lowered its full-year revenue range to $14,400 million to $14,550 million to reflect dollar strength. Adjusted EBITDA guidance is $3,345 million to $3,395 million, and Adjusted EPS guidance is $10.00 to $10.20. Third-quarter revenue guidance is $3,515 million to $3,565 million.

Jul 21, 2022 8-K

IQVIA Holdings 8-K Report, Material Agreement (Jun 16, 2022)

IQVIA Holdings Inc. (IQV) disclosed in a Current Report on Form 8-K dated June 16, 2022 that it entered into Amendment No. 1 to its Fifth Amended and Restated Credit Agreement. The amendment is among IQVIA Inc., IQVIA Holdings Inc., IQVIA RDS Inc. (the U.S. Borrower), other guarantors, Bank of America, N.A. as administrative agent and collateral agent, and the lenders party thereto. Under the amendment, the U.S. Borrower borrowed $1.25 billion in incremental Term A Loans. The company stated that proceeds will be used to repay approximately $950 million of outstanding revolving credit loans under the Credit Agreement and for general corporate purposes. The filing is brief and reports the transaction under Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation). The full terms of the amendment are set out in Exhibit 10.1, which is incorporated by reference and is not summarized further in this filing.

Jun 16, 2022 8-K

Shareholder MattersCorporate ChangesExhibits & Filings

IQVIA Holdings 8-K Report, Financial Results (Apr 27, 2022)

IQVIA Holdings Inc. (NYSE: IQV) reported first-quarter 2022 results on April 27, 2022, as furnished under Item 2.02 of Form 8-K through Exhibit 99.1. Revenue was $3,568 million, up 4.7 percent on a reported basis and 6.8 percent at constant currency. GAAP Net Income was $325 million, up 53.3 percent, and GAAP Diluted EPS was $1.68, up 54.1 percent. Adjusted EBITDA was $812 million, up 9.1 percent, and Adjusted Diluted EPS was $2.47, up 13.3 percent. R&DS contracted backlog reached $25.3 billion, up 9.1 percent year-over-year, and the company reported its highest-ever quarter of R&DS services bookings, over $1.9 billion. The company updated its full-year 2022 revenue guidance to $14,450 million to $14,750 million, citing the stronger US dollar and some disruption from the Ukraine/Russia crisis. It reaffirmed its full-year Adjusted EBITDA guidance of $3,330 million to $3,405 million and Adjusted Diluted EPS guidance of $9.95 to $10.25. For the second quarter, it guided revenue to $3,470 million to $3,520 million and Adjusted EBITDA to $790 million to $805 million. On the balance sheet, debt was $12,637 million and cash was $1,387 million, for net debt of $11,250 million and a Net Leverage Ratio of 3.6x trailing twelve-month Adjusted EBITDA. Operating Cash Flow was $508 million and Free Cash Flow was $331 million. The company repurchased $403 million of common stock in the quarter and had $2,120 million of authorization remaining.

Apr 27, 2022 8-K

IQVIA Holdings 8-K Report, Bylaw Amendment (Apr 14, 2022)

On April 12, 2022, IQVIA Holdings Inc. held its 2022 Annual Meeting of Stockholders, where stockholders approved a charter amendment to declassify the Board of Directors over time and provide for the annual election of all directors. The amended Amended and Restated Certificate of Incorporation took effect upon filing with the Delaware Secretary of State on April 12, 2022, and the Amended and Restated Bylaws, which the Board had approved subject to that stockholder vote, became effective the same day. At the meeting, four Class III director nominees were elected by majority vote: John P. Connaughton, John G. Danhakl, James A. Fasano and Leslie Wims Morris. The filing reports the for and withhold votes for each nominee, with 6,305,373 broker non-votes for each. The record date was February 15, 2022, when 190,912,001 shares of common stock were outstanding and entitled to vote. Stockholders also cast votes on an advisory vote on 2021 named executive officer compensation, an advisory shareholder proposal asking the Board to adopt majority voting in uncontested director elections, and ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2022. The filing reports the vote counts for each item, and the ratification received 159,537,862 votes for and 5,834,689 against.

Apr 14, 2022 8-K

Leadership ChangesExhibits & Filings

IQVIA Holdings 8-K Report, Executive Changes (Mar 14, 2022)

IQVIA Holdings Inc. (IQV) reported in this Current Report on Form 8-K, filed March 14, 2022, a leadership succession in its Research & Development Solutions (R&DS) business unit. Costa Panagos was appointed President of R&DS, effective April 1, 2022. Panagos has more than 25 years of industry experience serving life sciences customers and managing contract research organizations, and he joined the company in 1999. He currently serves as President, Research & Development Operations, responsible for the global delivery of all clinical trials, and previously served as CEO of Q2 Solutions, the company's global clinical trial laboratory business. Richard Staub III, the current President of R&DS, will retire from that role effective April 1, 2022. He will remain with the company as a senior advisor to the Chief Executive Officer, supporting business development, serving on customer governance boards, and ensuring a smooth transition. He will receive compensation commensurate with this new role, though the filing does not quantify it. The filing is primarily a management-transition disclosure. It includes a press release (Exhibit 99.1) in which Chairman and CEO Ari Bousbib described the succession as a long-planned process expected to be quick and seamless. The filing does not report financial results.

Mar 14, 2022 8-K

IQVIA Holdings 8-K Report, Financial Results (Feb 15, 2022)

IQVIA Holdings Inc. reported fourth-quarter and full-year 2021 results on February 15, 2022, in a press release furnished as Exhibit 99.1 under Item 2.02. Fourth-quarter revenue was $3,636 million, up 10.2 percent on a reported basis and 11.6 percent at constant currency. GAAP net income was $318 million and Adjusted EBITDA was $828 million, up 12.7 percent. For the full year, revenue was $13,874 million, up 22.1 percent reported, and GAAP net income was $966 million. Operating cash flow was $2,942 million and free cash flow was $2,302 million, which the company describes as a record. The company reaffirmed full-year 2022 revenue guidance of $14,700 million to $15,000 million, despite a $70 million foreign exchange headwind, and raised its Adjusted EBITDA guidance to $3,330 million to $3,405 million and Adjusted Diluted EPS guidance to $9.95 to $10.25. Guidance for the first quarter of 2022 calls for revenue of $3,515 million to $3,575 million. R&DS contracted backlog reached a record $24.8 billion, up 10.2 percent. Balance sheet and capital return items include cash of $1,366 million, debt of $12,125 million, net debt of $10,759 million, and a Net Leverage Ratio of 3.6x. The board approved a $2.0 billion increase in the share repurchase authorization on February 10, 2022, bringing remaining authorization to just over $2.5 billion.

Feb 15, 2022 8-K